PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Pharmacovigilance, department of pharmacology, Pasteur hospital, Bât J4, 30, avenue de la Voie-Romaine, CS51069, 06001 Nice Cedex 01, France.\', \'Centre régional de pharmacovigilance, 21079 Dijon, France.\', \'Centre régional de pharmacovigilance Paris-Cochin, 75014 Paris, France.\', \'Pharmacovigilance, department of pharmacology, Pasteur hospital, Bât J4, 30, avenue de la Voie-Romaine, CS51069, 06001 Nice Cedex 01, France. Electronic address: pharmacovigilance@chu-nice.fr.\']
?:citedBy
  • -1
?:creator
?:doi
  • S0040-5957(20)30091-310.1016/j.therap.2020.05.002
?:doi
?:hasPublicationType
?:journal
  • Therapie
is ?:pmid of
?:pmid
?:pmid
  • 32418730
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 0.293
?:rankingScore_hIndex
  • 32
is ?:relation_isRelatedTo_publication of
?:title
  • \'Off-label\' use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers.
?:type

Metadata

Anon_0  
expand all